AstraZeneca blames earnings nick on cost of biologics plant in Sweden

Over the long haul, AstraZeneca says the $285 million biologics plant it is building in Sweden will be a big winner as the company concentrates on cell-based drugs to build profits. For now, however, it's a drag.